Tadalafil Tablet, Film Coated
Product Images NDC 51655-063

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 51655-063). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tadalafil Tablets (5a958db7 5c0e 4cf0 9227 230886cf9bf8 01)

Chemical structure of the active ingredient Tadalafil, shown as a molecular diagram with labeled bonds and atoms characteristic of its chemical composition.*

FDA Label Image

Tadalafil Tablets (5a958db7 5c0e 4cf0 9227 230886cf9bf8 02)

A set of four line graphs showing the difference in blood pressure (BP) measurements between Tadalafil and placebo over time. The graphs depict Standing Systolic BP, Standing Diastolic BP, Supine Systolic BP, and Supine Diastolic BP, with time points ranging from 0 to 96 hours on the x-axes and BP difference in mmHg on the y-axes.*

FDA Label Image

Tadalafil Tablets (5a958db7 5c0e 4cf0 9227 230886cf9bf8 03)

A graph showing the effect of Tadalafil 20 mg combined with doxazosin 8 mg versus placebo with doxazosin 8 mg on standing and supine systolic blood pressure (mmHg) over 24 hours post-dose. The top plot depicts standing systolic blood pressure changes, and the bottom plot shows supine systolic blood pressure changes, with data points for both treatment groups over time.*

FDA Label Image

Tadalafil Tablets (5a958db7 5c0e 4cf0 9227 230886cf9bf8 04)

A line graph showing systolic blood pressure (mmHg) changes over 12 hours after administration of tadalafil or placebo combined with doxazosin. The graph compares four groups: 20 mg tadalafil at 08:00 with 8 mg daily doxazosin; placebo at 08:00 with 8 mg daily doxazosin; 20 mg tadalafil at 20:00 with 8 mg daily doxazosin; and placebo at 20:00 with 8 mg daily doxazosin. Systolic BP varies among the groups over time.*

FDA Label Image

Tadalafil Tablets (5a958db7 5c0e 4cf0 9227 230886cf9bf8 05)

A pharmacokinetic line graph depicting plasma tadalafil concentrations (µg/L) over time (hours) for three dosing regimens: a single 20-mg tadalafil dose, a single 5-mg tadalafil dose, and once-daily 5-mg tadalafil following 5 consecutive days of administration. The graph includes error bars showing variability at each time point.*

FDA Label Image

Tadalafil Tablets (5a958db7 5c0e 4cf0 9227 230886cf9bf8 06)

A line graph comparing change from baseline in IPSS total score over 12 weeks of treatment between Tadalafil 5 mg and placebo groups. The x-axis represents duration of treatment in weeks (0, 4, 8, 12), and the y-axis shows change from baseline IPSS total score, with both groups decreasing over time. Tadalafil shows a larger decrease in score compared to placebo, with significance noted at p<0.01.*

FDA Label Image

Tadalafil Tablets (5a958db7 5c0e 4cf0 9227 230886cf9bf8 07)

A line graph comparing the change from baseline in IPSS Total Score over 12 weeks of treatment between Tadalafil 5 mg and placebo groups. The x-axis shows treatment duration in weeks, and the y-axis shows the change in score. Tadalafil shows a greater reduction in IPSS Total Score compared to placebo, with statistical significance indicated at p<0.01.*

FDA Label Image

Tadalafil Tablets (5a958db7 5c0e 4cf0 9227 230886cf9bf8 08)

A line graph titled "Weeks of Therapy" showing the LS mean change from baseline over a 26-week period, comparing Tadalafil/Finasteride treatment with Placebo/Finasteride. The graph plots points at 0, 4, 12, and 26 weeks, indicating a greater reduction in LS mean change from baseline for the Tadalafil/Finasteride group compared to Placebo/Finasteride, with statistical significance annotations (p<0.001 and p<0.05) at specific time points.*

FDA Label Image

Tadalafil Tablets (5a958db7 5c0e 4cf0 9227 230886cf9bf8 09)

A line graph comparing the change from baseline in IPSS Total Score over 12 weeks of treatment for Tadalafil 5 mg and placebo. The x-axis shows treatment duration in weeks (0, 2, 4, 8, 12) and the y-axis shows the change from baseline score. The Tadalafil 5 mg group shows a greater decrease over time compared to placebo, with a statistically significant difference at 12 weeks (p<0.01).*

FDA Label Image

Label (51655 063 54 Rev A 09 22 Nhc)

Tadalafil 20 mg film-coated tablets, USP, oral dosage form. The label indicates a bottle containing 15 tablets manufactured by Northwind Health Company, LLC. It includes storage instructions to keep at controlled room temperature and warnings about tablet use. The product is prescription only (Rx only).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.